Aspen Pharmacare, South Africa's largest drugmaker, anticipates mid-single digit core earnings growth due to a sterile manufacturing contract for mRNA products.
Aspen Pharmacare, South Africa's largest drugmaker, expects mid-single digit earnings growth in its full-year core earnings due to a sterile manufacturing contract for mRNA products reaching the market in the second half. The company reported a 1% rise in H1 headline earnings and a 10% increase in group revenue to R21.1 billion ($1.11 billion). Normalised earnings before interest, tax, depreciation, and amortisation (EBITDA) rose 2% to R5.2 billion. Aspen anticipates mid-single digit growth in normalised EBITDA for its 2024 financial year.
March 04, 2024
3 Articles